Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials

Abstract Host-directed therapeutics targeting immune dysregulation are considered the most promising approach to address the unmet clinical need for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). To better understand the current cli...

Full description

Saved in:
Bibliographic Details
Published inOpen forum infectious diseases Vol. 9; no. 8; p. ofac381
Main Authors Wu, Qun, Pennini, Meghan E, Bergmann, Julie N, Kozak, Marina L, Herring, Kristen, Sciarretta, Kimberly L, Armstrong, Kimberly L
Format Journal Article
LanguageEnglish
Published Oxford University Press 01.08.2022
Subjects
Review
COVID-19
clinical trial
acute respiratory distress syndrome
host-directed therapy
sepsis
Online AccessGet full text

Cover

More Information
Summary:Abstract Host-directed therapeutics targeting immune dysregulation are considered the most promising approach to address the unmet clinical need for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). To better understand the current clinical study landscape and gaps in treating hospitalized patients with severe or critical COVID-19, we identified COVID-19 trials developing host-directed therapies registered at ClinicalTrials.gov and discussed the factors contributing to the success vs failure of these studies. We have learned, instead of the one-size-fits-all approach, future clinical trials evaluating a targeted immunomodulatory agent in heterogeneous patients with ALI/ARDS due to COVID-19 or other infectious diseases can use immune-based biomarkers in addition to clinical and demographic characteristics to improve patient stratification and inform clinical decision-making. Identifying distinct patient subgroups based on immune profiles across the disease trajectory, regardless of the causative pathogen, may accelerate evaluating host-directed therapeutics in trials of ALI/ARDS and related conditions (eg, sepsis).
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Potential conflicts of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Department of Health and Human Services or its components. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofac381